Market Research Logo

Metastatic Pancreatic Cancer - Pipeline Review, H2 2016

Metastatic Pancreatic Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Metastatic Pancreatic Cancer - Pipeline Review, H2 2016’, provides an overview of the Metastatic Pancreatic Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Pancreatic Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
    • The report reviews pipeline therapeutics for Metastatic Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Metastatic Pancreatic Cancer therapeutics and enlists all their major and minor projects
    • The report assesses Metastatic Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Metastatic Pancreatic Cancer
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Metastatic Pancreatic Cancer Overview
    Therapeutics Development
    Pipeline Products for Metastatic Pancreatic Cancer - Overview
    Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis
    Metastatic Pancreatic Cancer - Therapeutics under Development by Companies
    Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes
    Metastatic Pancreatic Cancer - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Metastatic Pancreatic Cancer - Products under Development by Companies
    Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes
    Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development
    AbbVie Inc
    Aduro BioTech, Inc.
    ArQule, Inc.
    Array BioPharma Inc.
    AstraZeneca Plc
    Axcentua Pharmaceuticals AB
    Berg LLC
    BioLineRx, Ltd.
    Bionomics Limited
    Boehringer Ingelheim GmbH
    Boston Biomedical, Inc.
    Bristol-Myers Squibb Company
    Celgene Corporation
    Clovis Oncology, Inc.
    Cornerstone Pharmaceuticals, Inc.
    CrystalGenomics, Inc.
    CTI BioPharma Corp.
    CytRx Corporation
    Daiichi Sankyo Company, Limited
    Eleison Pharmaceuticals LLC
    Eli Lilly and Company
    Ensol Biosciences Inc.
    Erytech Pharma SA
    F. Hoffmann-La Roche Ltd.
    Fountain Biopharma Inc.
    Gilead Sciences, Inc.
    GlaxoSmithKline Plc
    Immodulon Therapeutics Ltd.
    Incyte Corporation
    MabVax Therapeutics Holdings, Inc.
    Merck & Co., Inc.
    Merrimack Pharmaceuticals, Inc.
    NanoCarrier Co., Ltd.
    NantKwest, Inc.
    Natco Pharma Limited
    NewLink Genetics Corporation
    Novartis AG
    Oncolytics Biotech Inc.
    Oncovir, Inc.
    Oryx GmbH & Co. KG
    Pfizer Inc.
    Pharmacyclics, Inc.
    Phoenix Biotechnology, Inc.
    Precision Biologics, Inc.
    Rexahn Pharmaceuticals, Inc.
    Silence Therapeutics Plc
    Targovax ASA
    Tiltan Pharma Ltd.
    Tocagen Inc.
    Zeria Pharmaceutical Co., Ltd.
    Metastatic Pancreatic Cancer - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (curcumin + gemcitabine hydrochloride + paclitaxel) - Drug Profile
    5B1-ADC - Drug Profile
    acalabrutinib - Drug Profile
    aldoxorubicin hydrochloride - Drug Profile
    alpelisib - Drug Profile
    ARQ-761 - Drug Profile
    asparaginase - Drug Profile
    atezolizumab - Drug Profile
    Atu-027 - Drug Profile
    avasimibe - Drug Profile
    AXP-10711 - Drug Profile
    BI-853520 - Drug Profile
    binimetinib - Drug Profile
    BL-8040 - Drug Profile
    BNC-101 - Drug Profile
    Cellular Immunotherapy for Oncology - Drug Profile
    Cellular Immunotherapy for Oncology - Drug Profile
    Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile
    ceritinib - Drug Profile
    CG-200745 - Drug Profile
    Charis-1000 - Drug Profile
    CIM-1 - Drug Profile
    cisplatin - Drug Profile
    CPI-613 - Drug Profile
    dacomitinib - Drug Profile
    ensituximab - Drug Profile
    FB-704A - Drug Profile
    flucytosine ER + vocimagene amiretrorepvec - Drug Profile
    galunisertib - Drug Profile
    glufosfamide - Drug Profile
    GS-5745 - Drug Profile
    GSK-2256098 - Drug Profile
    haNK Program - Drug Profile
    HuMab-5B1 - Drug Profile
    ibrutinib - Drug Profile
    IMM-101 - Drug Profile
    INCB-52793 - Drug Profile
    indoximod - Drug Profile
    irinotecan hydrochloride - Drug Profile
    istiratumab - Drug Profile
    lapatinib ditosylate - Drug Profile
    LCL-161 - Drug Profile
    MesoCART - Drug Profile
    MK-2206 - Drug Profile
    MK-2206 + selumetinib sulfate - Drug Profile
    Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile
    MVT-1075 - Drug Profile
    napabucasin - Drug Profile
    nimotuzumab - Drug Profile
    NRCAN-019 - Drug Profile
    olaparib - Drug Profile
    paclitaxel albumin bound - Drug Profile
    palbociclib - Drug Profile
    Parvoryx - Drug Profile
    PBI-05204 - Drug Profile
    PCI-27483 - Drug Profile
    pelareorep - Drug Profile
    PLX-7486 - Drug Profile
    Poly-ICLC - Drug Profile
    PRI-724 - Drug Profile
    RG-7876 - Drug Profile
    ribociclib succinate - Drug Profile
    rottlerin - Drug Profile
    rucaparib camsylate - Drug Profile
    RX-0201 - Drug Profile
    SGT-53 - Drug Profile
    Small Molecules to Inhibit Lysyl Oxidase for Metastatic Pancreatic Cancer - Drug Profile
    sonidegib phosphate - Drug Profile
    TG-01 - Drug Profile
    TL-118 - Drug Profile
    tosedostat - Drug Profile
    trametinib dimethyl sulfoxide - Drug Profile
    ubidecarenone - Drug Profile
    ulixertinib - Drug Profile
    ulocuplumab - Drug Profile
    Vaccine for Oncology - Drug Profile
    veliparib - Drug Profile
    Z-360 - Drug Profile
    Metastatic Pancreatic Cancer - Dormant Projects
    Metastatic Pancreatic Cancer - Discontinued Products
    Metastatic Pancreatic Cancer - Product Development Milestones
    Featured News & Press Releases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Metastatic Pancreatic Cancer, H2 2016
    Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Development by Companies, H2 2016 (Contd..2)
    Number of Products under Development by Companies, H2 2016 (Contd..3)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Development by Companies, H2 2016 (Contd..3)
    Products under Development by Companies, H2 2016 (Contd..4)
    Products under Investigation by Universities/Institutes, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by ArQule, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Array BioPharma Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Berg LLC, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by BioLineRx, Ltd., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Bionomics Limited, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Boston Biomedical, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Celgene Corporation, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Clovis Oncology, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by CrystalGenomics, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by CTI BioPharma Corp., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by CytRx Corporation, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Eli Lilly and Company, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Ensol Biosciences Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Erytech Pharma SA, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Incyte Corporation, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Merck & Co., Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by NantKwest, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Natco Pharma Limited, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by NewLink Genetics Corporation, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Novartis AG, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Oncovir, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Pfizer Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Pharmacyclics, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Phoenix Biotechnology, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Silence Therapeutics Plc, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Targovax ASA, H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Tiltan Pharma Ltd., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Tocagen Inc., H2 2016
    Metastatic Pancreatic Cancer - Pipeline by Zeria Pharmaceutical Co., Ltd., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Metastatic Pancreatic Cancer - Dormant Projects, H2 2016
    Metastatic Pancreatic Cancer - Dormant Projects (Contd..1), H2 2016
    Metastatic Pancreatic Cancer - Dormant Projects (Contd..2), H2 2016
    Metastatic Pancreatic Cancer - Dormant Projects (Contd..3), H2 2016
    Metastatic Pancreatic Cancer - Dormant Projects (Contd..4), H2 2016
    Metastatic Pancreatic Cancer - Discontinued Products, H2 2016
    Metastatic Pancreatic Cancer - Discontinued Products (Contd..1), H2 2016
    Metastatic Pancreatic Cancer - Discontinued Products (Contd..2), H2 2016
    List of Figures
    Number of Products under Development for Metastatic Pancreatic Cancer, H2 2016
    Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Top 10 Routes of Administration, H2 2016
    Number of Products by Stage and Top 10 Routes of Administration, H2 2016
    Number of Products by Top 10 Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report